Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
ICH S1 prospective evaluation study: weight of evidence approach to predict outcome and value of 2-year rat carcinogenicity studies. A report from the regulatory authorities subgroup.
Bourcier T, McGovern T, Cavaliero T, Ebere G, Nishikawa A, Nishimura J, Ogawa K, Pasanen M, Vespa A, Van der Laan JW. Bourcier T, et al. Among authors: vespa a. Front Toxicol. 2024 Apr 11;6:1353783. doi: 10.3389/ftox.2024.1353783. eCollection 2024. Front Toxicol. 2024. PMID: 38665214 Free PMC article.
A Collaborative Initiative to Establish Genomic Biomarkers for Assessing Tumorigenic Potential to Reduce Reliance on Conventional Rodent Carcinogenicity Studies.
Corton JC, Mitchell CA, Auerbach S, Bushel P, Ellinger-Ziegelbauer H, Escobar PA, Froetschl R, Harrill AH, Johnson K, Klaunig JE, Pandiri AR, Podtelezhnikov AA, Rager JE, Tanis KQ, van der Laan JW, Vespa A, Yauk CL, Pettit SD, Sistare FD. Corton JC, et al. Among authors: vespa a. Toxicol Sci. 2022 Jun 28;188(1):4-16. doi: 10.1093/toxsci/kfac041. Toxicol Sci. 2022. PMID: 35404422 Free PMC article.
Determining recommended acceptable intake limits for N-nitrosamine impurities in pharmaceuticals: Development and application of the Carcinogenic Potency Categorization Approach (CPCA).
Kruhlak NL, Schmidt M, Froetschl R, Graber S, Haas B, Horne I, Horne S, King ST, Koval IA, Kumaran G, Langenkamp A, McGovern TJ, Peryea T, Sanh A, Siqueira Ferreira A, van Aerts L, Vespa A, Whomsley R. Kruhlak NL, et al. Among authors: vespa a. Regul Toxicol Pharmacol. 2024 May 14;150:105640. doi: 10.1016/j.yrtph.2024.105640. Online ahead of print. Regul Toxicol Pharmacol. 2024. PMID: 38754805 Free article.
Severity of effect considerations regarding the use of mutation as a toxicological endpoint for risk assessment: A report from the 8th International Workshop on Genotoxicity Testing (IWGT).
Parsons BL, Beal MA, Dearfield KL, Douglas GR, Gi M, Gollapudi BB, Heflich RH, Horibata K, Kenyon M, Long AS, Lovell DP, Lynch AM, Myers MB, Pfuhler S, Vespa A, Zeller A, Johnson GE, White PA. Parsons BL, et al. Among authors: vespa a. Environ Mol Mutagen. 2024 Jun 3. doi: 10.1002/em.22599. Online ahead of print. Environ Mol Mutagen. 2024. PMID: 38828778 Review.
Psychometric properties of the Italian version of the Revised Temperament and Character Inventory (TCI-140) in adults and older adults with cancer managed in outpatient settings.
Vespa A, Giulietti M, Gattafoni P, Fabbietti P, Berardi R, Arnaldi G, Balercia G, Salvio G, Ricciuti M, Spatuzzi R. Vespa A, et al. J Geriatr Oncol. 2023 Mar;14(2):101416. doi: 10.1016/j.jgo.2022.12.004. Epub 2023 Jan 13. J Geriatr Oncol. 2023. PMID: 36641835 No abstract available.
44 results